NovaBridge Biosciences Net Income (Loss) Available to Common Stockholders, Basic
NovaBridge Biosciences (NBP) reported Net Income (Loss) Available to Common Stockholders, Basic of -CNY 1.47 billion for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-30.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-04-30
- NovaBridge Biosciences net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was 1.04B CNY.
- NovaBridge Biosciences net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was -381.62M CNY.
CNY
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2023-12-31 | -1.47B CNY 20-F · filed 2024-04-30 | |||
| 2022-12-31 | -2.51B CNY 20-F · filed 2024-04-30 | |||
| 2022-06-30 | -1.05B CNY 6-K · filed 2022-11-10 | |||
| 2021-12-31 | -2.33B CNY 20-F · filed 2024-04-30 | |||
| 2021-06-30 | -1.08B CNY 6-K · filed 2022-11-10 | |||
| 2020-12-31 | 1.04B CNY derived: 20-F 12 month − 6-K 9 month · filed 2023-05-01 | 470.92M CNY 20-F · filed 2023-05-01 | ||
| 2020-09-30 | -570.63M CNY 6-K · filed 2021-02-05 | |||
| 2019-12-31 | -381.62M CNY derived: 20-F 12 month − 6-K 9 month · filed 2022-04-29 | -1.49B CNY 20-F · filed 2022-04-29 | ||
| 2019-09-30 | -1.10B CNY 6-K · filed 2021-02-05 | |||
| 2018-12-31 | -402.83M CNY 20-F · filed 2021-04-28 | |||
| 2017-12-31 | -298.24M CNY 20-F · filed 2020-04-29 |
USD
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$206.44M 20-F · filed 2024-04-30 | |||
| 2022-12-31 | -$363.53M 20-F · filed 2023-05-01 | |||
| 2022-06-30 | -$156.29M 6-K · filed 2022-11-10 | |||
| 2021-12-31 | -$365.87M 20-F · filed 2022-04-29 | |||
| 2020-12-31 | $156.22M derived: 20-F 12 month − 6-K 9 month · filed 2021-04-28 | $72.17M 20-F · filed 2021-04-28 | ||
| 2020-09-30 | -$84.05M 6-K · filed 2021-02-05 | |||
| 2019-12-31 | -$213.31M 20-F · filed 2020-04-29 |